Potential predictors of CMV reactivation were: early CD4 + and absolute lymphocyte count after the first cycle of R-BENDA; high tumor burden; and the presence of B symptoms (Isono et al. 2016; Saburi et al. 2023; Pezzullo et al. 2021; Ito et al. 2024). This evidence concerns the gene CD4 and neoplasm.